Background High medicines prices are a barrier to medicines access, and their impact is greater in developing countries. Objective This study assessed the availability, prices and affordability of medicines in public and private sectors in Malaysia to understand the pharmaceutical environment and guide policy recommendations. Methods This nationwide cross-sectional study adapted the World Health Organization/Health Action International (WHO/HAI) methodology. A total of 87 premises from both public and private sectors participated in this study. Data on 50 medicines were collected to analyze availability, prices and affordability. Medicine prices were compared against the international reference prices (IRPs), and affordability was assessed by daily income level. Results In the public sector, the average availability of generics (74.8%) was higher than that of the originator brand name products (19.4%). However, in the private sector, the availability of originator brands was higher (52.2%) than generics (49.1%). Procurement prices in the public sector were up to 1.5 times the IRPs, but up to 8.4 times in the private sector. The study also observed large price variation across medicines in the private sector. Median retail mark-ups in private hospitals (generics 166.9%; originators 51.0%) were higher than in retail pharmacies (generics 94.7%; originators 22.4%). Generics were generally affordable, but originator brands were unaffordable. Conclusion Current policies on generic medicines need to be strengthened to improve the availability and use of generics in the country. High medicine prices and large price variation in the current free market suggest that coherent pricing policies and regulations are needed to safeguard the accessibility and affordability of medicines for the people.
Introduction
The high prices of medicines are a severe burden to public health care worldwide, but the negative impact on access and affordability is greater in developing countries [1] [2] [3] . Besides being barriers to medicines access, high out-ofpocket (OOP) expenses may force people into impoverishment [4, 5] . Correspondingly, the World Health Organization (WHO) highlighted that fair pricing and effective financing are pillars to equitable medicine access and universal health coverage [3, 6] .
Malaysia as an upper middle-income country recorded health spending of 4.49% of gross domestic product (GDP) (approximately 12.5 billion US dollars [USD]) in 2014 [7] . The health care system is made up of the public and private sectors. Public health services are financed through general taxation, while private health services are funded by private insurance, employers and OOP payments [8, 9] . In the public sector, the Ministry of Health's (MOH's) medicine expenditure increased more than 10-fold in 20 years, from USD50 million (1995) to USD580 million (2015) [10, 11] . Medicine expenditure (including overthe-counter and prescription medicines) in the private sector has also increased with a similar trajectory, with USD590 million spent in 2014 [7] . In the same year, the average expenditure of the public and private sectors were estimated to be 44% and 56%, respectively [12] . In addition, OOP expenditures in 2014 accounted for 39% of total health expenditure (THE) and 82% of private sector health expenditure [7] .
Importantly, at the time this study was conducted, there was no price control on pharmaceuticals in Malaysia. In the public sector, the MOH is the largest pharmaceutical spender and has the purchasing power to influence prices in a monopsony market [13, 14] . A large proportion of medicines are procured centrally through concession supply and national tender. The competitive tender procedure follows procurement guidelines of the Ministry of Finance, and an award is made to the most advantageous tenderer [15, 16] . Internal and external price referencing policies are also used to benchmark prices in price negotiations [16, 17] . For medicines not included in the central procurement, individual premises may procure them via the local purchase method [15, 17, 18] .
In the private sector, however, manufacturers, distributors and retailers may offer any prices in the free market without any pricing policy or regulation [19, 20] . Although chain hospitals and retail pharmacies may negotiate prices centrally to obtain more favorable prices, evidence over the years has shown that medicine prices and mark-ups in Malaysia are higher than international reference prices (IRPs) and costs in other countries [18, 19, [21] [22] [23] [24] [25] . Additionally, anti-competitive practices such as monopoly, collusion, and price discrimination have been reported to result in an unhealthy pharmaceutical market and unaffordable medicines [25] [26] [27] .
Regulatory and monitoring strategies that are essential to promote fair pricing are often absent or poorly implemented in developing countries [3, 13] . Further, rising OOP expenditures, increasing overall cost of living, coupled with declining purchasing power increase financial risk for individuals and puts pressure on providers [9, 20, 25, 28] . For these reasons, information on the pharmaceutical supply chain, its structure and current prices is crucial in order to formulate coherent policies. To the best of our knowledge, this is the first large-scale, nationwide study using the World Health Organization/Health Action International (WHO/ HAI) methodology. A few recent studies on pharmaceutical pricing were limited to specific cities and the private sector [21, 29, 30] . Thus, this study attempts to examine current information on the availability, price and affordability of selected important medicines in both public and private sectors to provide a comprehensive understanding of the pharmaceutical sector in Malaysia.
Methods
A nationwide cross-sectional survey measuring the availability, price and affordability of medicines price was conducted in 2017, using the WHO/HAI guidelines [6] . In this survey, six major cities in Malaysia representing different geographical zones in the country were used as survey areas. Data on availability and patient prices were collected in sample outlets in both public and private sectors.
Selection of Premises
In each survey area, five public premises were systematically selected to obtain public sector prices. First, the State's General Hospital was selected as the main public hospital. Two public hospitals (defined as MOH hospitals which are typically secondary or tertiary hospitals) and two health clinics were then randomly selected within a radius of 50 km from the main public hospital. The 50-km radius was determined to provide a sufficient number of premises for randomization and optimized for appropriate representation of the six survey areas in the country. In addition, three university hospitals from the public sector were included in the study to allow comparison with teaching hospitals.
The selection of premises in the private sector was based on proximity to the selected public premises. For retail pharmacies, one premise located within 10 km of each selected public premise was selected as the study sample. As the participation in the private sector was voluntary, only private premises that consented to participate were included. Due to the limited number of private hospitals available, all private hospitals in the survey area that gave consent to participate were included in the study. Children hospitals, maternity and women hospitals, and hospitals with less than 30 beds were excluded from the study.
Selection of Medicines
A total of 50 medicines were surveyed. Data were collected from 14 WHO global core list medicines (Online Resource 1 in the electronic supplementary material) and 36 national supplementary list medicines (Online Resource 2). The national supplementary list medicines were based on local disease burden and utilization. Four oncology and four onpatent innovator medicines were included in the supplementary list to capture information on expensive medicines that were deemed of special interest to the country.
Data Collection
For each medicine surveyed, availability and price data were collected for both the originator brand name (also called trade name) drug and the lowest-priced generic equivalent. Regarding prices, two types of prices were collected, namely the procurement price and patient price. The procurement price is the price paid by the government, wholesalers, retailers and other purchasers to procure the medicines. In the public sector, procurement prices of medicines contracted at the national level were centrally collected at the MOH. For local purchase items, procurement prices were collected from the respective premises. As medicines are provided free to care seekers in the public sector, patient prices were only collected for the private sector. Patient price is defined as the retail price on the price labels charged to consumers at retail pharmacies or the price charged to patients at private hospitals.
For results to be comparable, data were collected only for the specified dosage forms and strengths. To minimize variation in price due to economies of scale, data were collected for the recommended pack size or on the next largest pack size. Data entry into a standardized form was validated by a systematic check for completeness of information, suspected erroneous entries or obvious outliers. Survey managers and area supervisors verified questionable data by contacting the pharmacist at the respective health care premise.
Data Analysis
Availability was reported as the percentage of premises in which the medicine was found on the day of data collection and was classified as very low (< 30%), low (30-40%), fairly high (50-80%) and high (> 80%) [31] . Price is expressed as price per unit (e.g., dose, tablet). The lowest procurement price (after any bonus or discount) and lowest patient price (after any discount) recorded were used. For international comparison, the 2015 IRPs from the Management Sciences for Health (MSH) database were utilized [32] . IRPs are prices offered by mostly not-for-profit suppliers to developing countries and are recommended as the standard to compare prices between countries [6] . Procurement prices of 41 medicines with IRPs were computed and reported as median price ratios (MPRs). The MPR is the ratio of the median price for each medicine across premises divided by the median IRP converted into local currency. Prices in different subgroups were compared within and between the public/ private sectors for both procurement and patient prices. Price ratios between the 25th (Q25) and 75th percentile (Q75) are used to study the price variation across the pharmaceutical market. Mark-up was calculated as the percentage increase from procurement price to patient price.
Affordability was assessed by the number of days' wages of the lowest paid unskilled government worker required to purchase selected courses of treatment for common acute and chronic conditions. Standard treatments are deemed as full courses of therapy for acute conditions and a 1-month course of therapy for chronic conditions. The daily salary of the lowest paid unskilled government worker used was 58.17 Malaysian Ringgit (MYR) (USD13.50; USD1 = MYR4.31) [33] [34] [35] [36] . This study included an additional comparison with the daily lowest minimum wage of MYR35.38 (USD8.21; 1 USD = MYR4.31) as determined by the Federal Government of Malaysia to better represent the low-income population [37] .
Descriptive statistics were employed to present the data in averages, medians and interquartile ranges (IQRs). All data were analyzed using STATA/IC version 13. 
Results
A sample of 87 premises comprising 33 public and 54 private premises participated in the study (Table 1) .
Availability
Overall, the average availability of the medicines surveyed was high (83.0%) in the public sector and fairly high (66.7%) in the private sector (Table 2 ). In the public sector, the average availability of generics was almost four times higher than originators (74.8% and 19.4%, respectively). In contrast, the private sector availability of originators was slightly higher than generics (52.2% and 49.1%, respectively). The results revealed that the average availability of generics was higher than originators in all types of public premises: public hospitals (75.9% and 16.8%, respectively), health clinics (77.4% and 22.0%, respectively) and university hospitals (72.5% and 29.7%, respectively). For the private sector, only retail pharmacies recorded a higher availability of generics than originators (52.2% and 43.1%, respectively). The average availability of originators was higher than generics (65.7% and 45.6%, respectively) in private hospitals. Both global core list and supplementary list medicines were found to have higher availability in the public sector compared to the private sector (global 81.2% vs 65.7%; supplementary 83.7% vs 67.1%). When stratified by location, it was found that the availability of medicines was higher in Peninsular Malaysia as compared to East Malaysia. Table 3 summarizes the MPRs (ratio of median price/ median IRP) of the medicines surveyed for both the public and private sectors. The procurement MPR for the originator was 8.4 times the IRP (IQR 4.4-23.8). For the lowestpriced generic medicines, the procurement MPR was 2.0 times the IRP (IQR 1.1-3.7). The median procurement MPR of originator brand products in the private sector (8.6, IQR 4.6-23.8) was more than five times higher as compared to the public sector (1.2, IQR 0.6-5.2). For lowest-priced generics, the median procurement MPR in the private sector (2.5, IQR 1.4-4.0) was slightly higher than for the public Table 1 Number of premises sampled, by survey area and sector
Prices
The majority of retail pharmacies that consented to participate in the study were independent pharmacies. Two public hospitals, one health clinic and three retail pharmacies were located in the rural area. Back-up premises were selected for all sample premises except private hospitals. Eight back-up premises were visited when the primary retail pharmacies had less than 50% of the medicines included in this study Table 2 Average medicines availability, percentage by product type, group, location and sector a Number listed is the total number of medicines and number of premises in this study. Availability calculation is based on expected availability in the type of premise. For example, oncology medicines were excluded from retail pharmacies, health clinics and hospitals without oncology services. Therefore the actual number of medicines and number of premises used in the calculation of availability may be different according to subgroup categories and premise types b Premise may have both originator and generic products. Original or generic brands not available in Malaysia were omitted c Number of premises listed is the total number of premises in both Peninsular and East Malaysia. Actual number of premises used in the calculation of availability can be found in To compare prices between and within groups, median procurement and patient prices of matched pairs of medicines were compared and reported as ratios (Table 4) . Comparing product types, procurement prices of originators were 6.6 (IQR 4.9-11.7) times that of generics. Comparing sectors, private premises procured medicines at 2.3 (IQR 1.2-7.5) times the costs of public premises. Specifically, the procurement prices of private hospitals and retail pharmacies were 3.3 (IQR 1.3-9.7) and 2.3 (IQR 1.1-5.1) times the public sector prices, respectively. In the case of university hospitals and public hospitals, results show that prices in these public institutions are generally comparable despite having different procurement mechanisms. Likewise, private hospitals and retail pharmacies reported similar procurement prices in the private sector.
Comparison of median patient prices revealed a trend consistent to that of procurement prices, whereby selling prices of originator products were about 2.8 (IQR 1.9-3.9) times that of generic products. On the other hand, private hospitals were found to charge patient prices 1.4 (IQR 1.2-1.8) times that of retail pharmacies. Within-group comparison of originator and generic products found that the median patient prices of private hospitals were 1.2 times that of retail pharmacies for both groups.
Across all medicines regardless of product type, the median procurement price data show that there was almost no variation (price ratio of Q75/Q25) in the public sector (1.01). However, a substantial variation in the private sector (1.78) was noted. Across all sectors, median procurement price examination by product type showed that there was a small variation across originator medicines (1.12) and a wider variation across generics (1.95). A separate analysis for the public sector alone revealed that prices were stable across originators (1.00) and generics (1.01). On the contrary, the private sector had a small variation across originators (1.08) and a wider variation across generics (1.35). Regarding patient prices in the private sector, the variation was smaller across originators (1.33) compared to generics (1.53). Table 5 summarizes the mark-ups of procurement price to patient price in the private sector by product type. Comparing median retail mark-ups across product types, lowest-priced generics had higher mark-ups than originators in both private hospitals (166.9%, IQR 120.2-232.5%, vs 51.0%, IQR 35.6-59.2%) and retail pharmacies (94.7%, IQR 60.0-162.3%, vs 22.4%, IQR 18.4 -27.8%). For both types of products, median mark-ups of private hospitals were higher than that of retail pharmacies. Further analysis on relationship between mark-up and procurement unit price range for medicines in tablet form showed that median mark-ups decreased as the procurement prices increased (Online Resource 3). Specifically for originator products, median mark-ups decreased with increasing procurement price from 37.0% (medicine cost ≤ MYR1.00) to 18.9% (medicine cost > MYR10.00). In the case of lowestpriced generics, median mark-ups decreased from 118.2% (medicine cost ≤ MYR1.00) to 37.0% (medicine cost = MYR2.01-MYR5.00).
Affordability
Affordability was analyzed only for the private sector since medicines are provided free in the public sector. For the purpose illustration in this article, one medicine was chosen from each of the ten disease conditions to study the affordability of medicines (Table 6 ). The selection was based on the global core list recommended by WHO/HAI and local utilization [6, 12] . Generic products generally cost less than 1 day's wages and were affordable for people with a low income level, except for amitriptyline 25 mg tablet and omeprazole 20 mg tablet. On the contrary, patients need to pay more than 1 day's wages for a number of originator products. For example, a 1-month supply of simvastatin 20 mg for hyperlipidemia would cost 1.4 days' wages of a government worker or 2.4 days' wages of a worker on the lowest minimum wage. Gefitinib 250 mg for treatment of cancer required about 4 months' wages of a government worker and more than 6 months' wages of the lowest minimum wage worker. It is interesting to note that omeprazole 20 mg tablets cost about 6 days' wages or more even when there are a number of generic brand equivalents in the market. Further analysis by disease categories showed that treatment costs with originator products were 2.1-4.7 days' of minimum wage for asthma, central nervous system disorders, cardiovascular disease, depression, diabetes, infectious disease, and peptic ulcer (Online Resource 4). Additionally, cancer treatment costs were more than 6 months' salary. When generic products were used in place of the originators, treatment costs for most of the disease categories became affordable (less than 1 day's wages), except for depression and cancer treatment.
Discussion

Availability
The higher availability of generics compared with that of originators in the public sector reflects the positive impact of the Generic Medicines Policy. This policy is one of the components highlighted in the Malaysian National Medicines Policy (MNMP) to promote the use and procurement of generic medicines [38] . However, the availability of generics was lower in the private sector. This observation could be due to the different practice and preference in the private sector as reported in earlier studies. The studies found that the majority of physicians from private medical centers had negative perceptions about the safety, quality and efficacy of generic medicines and a poor understanding of bioequivalence testing [39, 40] . Comparing the results in this study with those of other countries, the average medicines availability in Malaysia's public sector is higher than in the Western Pacific Region (43%, range 22.2% in the Philippines to 79.2% in Mongolia), South East Asia Region (38.3%, range 16.3-57.9%) [2] , and China (median availability range 38.9-44.4%) [41] . It should be noted, however, that these studies were conducted much earlier, with different baskets of medicines.
Prices
According to the WHO guideline [42] , the procurement process is considered efficient for middle-income countries when the median price is less than three times the IRP, i.e., an MPR below three. Based on this indicator, public procurement in Malaysia was efficient. This is largely facilitated by public sector procurement policies to obtain prices that are of best value in relation to the required technical specifications [15] and the Generic Medicines Policy [38] . Although the private sector may not be subjected to the benchmark of three times the IRP, a number of medicines purchased had high MPRs. This could be explained by the smaller purchasing volume and individual procurement carried out by private premises. Therefore, procurement prices were higher, as opposed to the public premises, which have advantage in economies of scale.
In terms of price variation, there was almost negligible price differences across the public sector, as the majority of the medicines are purchased at standardized prices. The very small price variation was mainly contributed by local purchase medicines and university hospitals, which have different procurement contracts. On the contrary, there was a wide price variation in the private sector, as the same product may have different prices across premises due to the absence of pricing regulation in Malaysia [14, 19, 21, 23] . Similar to what has been seen in other studies, competition among the generic brands in the market contributed to wider price variation in generics than in originators [43, 44] . Nevertheless, a few off-patent originators were procured at relatively high prices even when multiple generic brands were available in the market. This suggests that the competition in the free market is not reducing prices effectively, and therefore policies on pharmaceutical pricing are needed.
Another key contributor to price variations is the differential pricing, bonuses, discounts and rebates offered by industry players to different dispensing premises [14, 25, 45] . These pharmaceutical trading practices suggest that the prices of medicines could actually be lowered to provide fairer pricing for the people [24] . In response to unfair trade practices, the Good Pharmaceutical Trade Practice (GPTP) guideline was released by the Pharmaceutical Services Division, MOH Malaysia in 2015 to promote standard prices and bonus schemes [17, 25] . However, it is an administrative order that is not legally binding. As a result, adherence is poor, as it relies on the goodwill of the pharmaceutical companies [46, 47] .
Procurement price to patient price mark-ups found in this study were higher than those in other upper-middle-income countries (UMIC) such as Brazil (22%), Kazakhstan (lowestpriced generic 20-30%) and Peru (originator 11%, lowestpriced generic 70%) [48] . Furthermore, the maximum retail mark-up of 900% reported in the private hospitals is markedly high. Although it is not uncommon to have revenues from pharmaceutical mark-ups for cross-subsidization of income to finance hospitals, the practice does pose a moral hazard [49] [50] [51] [52] [53] . Besides the ethical concern of high medicine mark-ups to cover operational costs, providers may be inclined to induce additional demand for medicines.
Affordability
According to the WHO's recommendation, treatment that requires less than 1 day's wages is deemed affordable [6] . Many studies have shown that treatments using generic medicines are more affordable, whereas those with originator brands tend to be less affordable for the low-income population [2, 19, 23, 43] . This is further substantiated by the results of this study, whereby treatments for highly prevalent non-communicable diseases in Malaysia-such as cardiovascular disease, diabetes, depression and cancer-are unaffordable and coincide with the high availability of originators in the private sector. These factors coupled with the fact that patients rely heavily on physicians' decisions may affect accessibility and patient outcomes. This is because those who have a low income may not be able to afford continuous treatment or pay more for a treatment not knowing that there are cheaper options available [2, 14, 19] .
Policy Implication
The Malaysian government commitment to ensuring access to medicines through the MNMP has improved the availability and affordability of medicines. However, there are still gaps in the implementation of the Generic Medicines Policy between public and private sectors. Regulations that enforce mandatory substitution have been shown to be effective in promoting the use of generic medicines and curbing the escalation of pharmaceutical expenditure [54, 55] . Policies that include financial incentives for dispensing of generic brands will also increase the use of cheaper generic options [17, 56] . To increase the affordability of generic medicines, it is important for policy makers to encourage stakeholders to consider adoption of pricing strategies that effectively reduce costs, such as internal reference pricing, where prices are set according to prices of medicines in therapeutic equivalent groups [13, 57] . Besides that, there are also countries that use obligatory price reduction by which generics are required to be priced at least 20-50% lower than the originators [58, 59] . The pharmaceutical market does not have perfect competition like other commodities, as a result of information asymmetry between the prescriber and the buyer [14, 25, 60] . Under these circumstances, government regulations and coherent policies are crucial to correct the market failure and promote efficiency [25, 60, 61] . As part of the overall reform to provide equitable access, regulations at different points along the supply chain such as fixed prices and markup regulation are among the many pricing policies implemented worldwide [13, 54] . Fixed patient prices will enable every patient to obtain medicines at fair prices and prevent unnecessary travelling time to find the most affordable medicines. In addition, pricing regulation that includes a regressive component is used by many countries and leads to better outcomes than fixed percentage mark-ups, as regressive mark-up drives retailers to maximize profit by selling lower price medicines which have higher mark-ups, encouraging the dispensing of less expensive medicines [54] .
Regarding price variation, it is not uncommon to have price differences within a country when public and private sectors have separate procurements [14, 17] . However, differential pricing (also known as discriminatory or tiered pricing) does not encourage sustainability or autonomy in low-and middle-income countries, and results in variable prices within and between countries [13, 25] . Furthermore, rational pricing should be based on novelty, efficacy and actual research costs rather than how much the market will bear [62, 63] . The present study highlights opportunities to narrow price variation between sectors and different health care premises. First, the GPTP needs to be legally binding to enable the enforcement of non-discriminatory trade practices. Equally important, the adoption of price referencing by the private sector, such as the mechanism currently utilized in the public sector, will harmonize prices within the country. To address this, a price-sharing platform to exchange procurement information at the national or even crosscountry level will facilitate price benchmarking and improve negotiation positions [25, 64] . Purchasing policies such as pooled purchasing among different procurement centers will also maximize bargaining power [6, 13, 65] .
Notwithstanding, reform strategies need to encompass consumer education and price transparency to empower consumers [13, 25] . The reinforcement of the existing Consumer Price Guide information available on the public domain will help to disseminate reliable price information to guide consumers and payers. Besides that, adequate enforcement is needed for the discussed policies to succeed [48] . After the initial price-setting mechanisms are in place, other measures such as limits or freezes of inflationary price increases may be considered for price reviews [43, 60, 66] . Moving forward, health technology assessment and value-based pricing are increasingly powerful tools in the determination of medicine pricing, particularly for high-cost innovators [14, 66] . Table 5 Median mark-ups of procurement price to patient price in the private sector by product type Given these points, it is important to recognize the need to balance between fair pricing and sustainable health care. Although Malaysia has achieved universal health coverage (UHC) through an extensive public healthcare system providing comprehensive health care at minimal OOP cost, policies to address the systemic disparity between the public and private sectors and to ensure the sustainability of UHC are needed [8, 67, 68] . Alternative financing mechanisms need to be established to address the issue of high patient prices and cross subsidization in private premises [2, 14] . Major health reforms for National Health Insurance have been discussed, and it is likely that a social health insurance, a single purchaser and integration of services between both public and private provision would be established in the long run [69, 70] .
Study Limitations
Similar to other studies conducted using the WHO/HAI methodology, availability was measured on the day of data collection for a predetermined list of medicines and therefore did not account for other strengths, dosage forms and therapeutic alternatives. However, the availability results reflect the real-life situation faced by patients when they visit a health care premise. Regarding price comparison with IRP, a number of medicines selected in this study did not have an IRP and therefore an MPR comparison was not available. Another limitation is that the reliability of MPRs is dependent on the number of supplier prices on the MSH database that are used to determine the median IRP. In cases where very few supplier prices are available or when the buyer price is used as a proxy, MPR results can be skewed by a particularly high or low IRP. Finally, the sample of premises and medicines were systematically selected according to the WHO/HAI methodology and were not matched between the public and private sectors. The methodology is designed to be adaptable in any situation and has been widely used in more than 50 countries to generate evidence on medicines prices and availability. Nevertheless, the results may be limited by the small sample size and other confounding factors.
Conclusion
The present study provides comprehensive information to add to the limited literature on availability, prices and affordability of medicines, and highlights the issues regarding pharmaceutical pricing in Malaysia. Although the high availability of generics in the public sector is aligned with the MNMP, the use of generics in the private sector needs to be improved. In the shorter run, the efficient procurement in the public sector suggests that buyer strategies such as pooled procurement, price referencing and negotiation could be adopted by the private sector to stimulate higher savings. The findings suggest the need for policy interventions to address the large price variations and high mark-ups in the private sector. Moving forward, promotion and incentives for generic medicine use need to be integrated with aggressive pricing regulations and sustainable health financing mechanisms to safeguard access and affordability of medicines for the people.
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